Table 1.
Details on the drugs used for pre-treatment.
| Drug used for pre-treatment | Drug classification and purpose | Dose (μmol/kg), time before 4-AP | Reference for function or effective dose |
|---|---|---|---|
| TEA | BKCa inhibitor, to test 4-AP KV selectivity | 35 | Berg and Koteng (1997) |
| Glibenclamide | KATP inhibitor, to test 4-AP KV selectivity | 40 | Berg and Koteng (1997) |
| Hexamethonium chloride | Peripheral nAChR antagonist, ganglion blockade | 37 | Wassermann (1971), Berg (2005) |
| Atropine sulfate | Mainly peripheral mAChR antagonist | 6.9, −20 min | Vargas and Ringdahl (1990), Berg (2002) |
| Scopolamine hydrobromide | Mainly central mAChR antagonist | 2.4, −30 min | Vargas and Ringdahl (1990), Berg (2002) |
| Reserpine | Depletes sympathetic nerves of norepinephrine | 2 × 8.2, i.p., −48 + −24 h |
Berg (2002) |
| Phentolamine | Non-selective αAR antagonist | 6.3 | Berg (2002, 2005) |
| Prazosin | α1AR antagonist | 0.24 | Berg (2003, 2005) |
| Yohimbine | α2AR antagonist | 5 | Berg (2003) |
| Nadolol | Peripheral β1 + 2AR antagonist | 8.5 | Berg et al. (2010) |
| SR59230A | β3AR antagonist | 10, −5 min | Malinowska and Schlicker (1997), Berg et al. (2010) |
| Desipramine hydrochloride | Inhibits norepinephrine reuptake | 44, i.p., −4.5 h | Miralles et al. (2002), Berg et al. (2009) |
SR59230A was from Tocris Bioscience, Bristol, UK; the remaining drugs from Sigma Chemical Co., St. Louis, MO, USA. The drugs were administered i.v. as bolus injections (0.6–1 ml/kg) 10 min prior to 4-AP, unless otherwise indicated.